(Albany, USA) “B-Cell Lymphoma Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the B-Cell Lymphoma Market.
The B-Cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ B-Cell Lymphoma Pipeline Analysis
Some of the key takeaways from the B-Cell Lymphoma Pipeline Report:
- B-Cell Lymphoma Companies across the globe are diligently working toward developing novel B-Cell Lymphoma treatment therapies with a considerable amount of success over the years.
- B-Cell Lymphoma companies working in the treatment market are Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Guangzhou Lupeng Pharmaceutical, TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Nanjing Legend Biotech Co.and others, are developing therapies for the B-Cell Lymphoma treatment
- Emerging B-Cell Lymphoma therapies such as Epeleuton, Tipelukast, TA 270, MW 001, PTC 857, Baicalein, VLX 1005, Research programme: 5-B-Cell Lymphoma Inhibitor (LOX Inhibitor), and others are expected to have a significant impact on the B-Cell Lymphoma market in the coming years.
- In March 2023, Oncternal Therapeutics, Inc. initiated a trial titled, “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma”. This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study that will be conducted in multiple phases inpatients with R/R MCL. The study phases will include a Screening Phase, an Open-Label Ibrutinib Monotherapy Treatment Phase, a Randomized Double-Blind Treatment Phase, and a Long-Term Follow-Up Phase. When patients meet all study eligibility requirements in the Screening Phase, they will enter the Open-Label Ibrutinib Monotherapy Treatment Phase and will receive ibrutinib alone daily. The trial is currently active with 365participants and is anticipated to be complete by November 2026.
B-Cell Lymphoma Overview
B-cell lymphoma is a type of non-Hodgkin lymphoma that originates in the B-cells. It is the most common type of lymphoma and about 85% of all lymphomas in the United States are B-cell. Common symptoms associated with lymphoma include painless enlargement of one or more lymph node areas, fever, night sweats, and weight loss. Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma. DLBCL typically affects older people and accounts for one out of three cases of non-Hodgkin lymphoma. This type of B-cell lymphoma usually begins as a mass in a lymph node, but can also form in particular sites such as bone, intestine, the spinal cord or brain. Standard treatment for DLBCL generally involves months of conventional chemotherapy, and overall cure rates in the last 15 years have been about 70%. Diffuse large B-cell lymphoma has long been treated as a single disease, but it is now categorized into many different subtypes based on their molecular features. There are two large subtypes: germinal center b-cell (GCB) and activated b-cell (ABC). B-cell lymphomas arise from different stages of differentiation of B-cells and constitute a broad spectrum, extending from small- to large-cell types, and from low to high grades of clinical behavior.
Get a Free Sample PDF Report to know more about B-Cell Lymphoma Pipeline Therapeutic Assessment @ B-Cell Lymphoma Treatment Market
B-Cell Lymphoma Route of Administration
B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical
B-Cell Lymphoma Molecule Type
B-Cell Lymphoma Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
B-Cell Lymphoma Pipeline Therapeutics Assessment
- B-Cell Lymphoma Assessment by Product Type
- B-Cell Lymphoma By Stage and Product Type
- B-Cell Lymphoma Assessment by Route of Administration
- B-Cell Lymphoma By Stage and Route of Administration
- B-Cell Lymphoma Assessment by Molecule Type
- B-Cell Lymphoma by Stage and Molecule Type
DelveInsight’s B-Cell Lymphoma Report covers around 170+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further B-Cell Lymphoma product details are provided in the report. Download the B-Cell Lymphoma pipeline report to learn more about the emerging B-Cell Lymphoma therapies @ B-Cell Lymphoma Therapeutics Assessment
B-Cell Lymphoma Pipeline Analysis:
The B-Cell Lymphoma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Lymphoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Lymphoma Treatment.
- B-Cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Lymphoma market.
Download Sample PDF Report to know more about B-Cell Lymphoma drugs and therapies @ B-Cell Lymphoma Clinical Trials and FDA Approvals
Scope of B-Cell Lymphoma Pipeline Drug Insight
- Coverage: Global
- Key B-Cell Lymphoma Companies: Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Guangzhou Lupeng Pharmaceutical, TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Nanjing Legend Biotech Co.and others.
- Key B-Cell Lymphoma Therapies: Epeleuton, Tipelukast, TA 270, MW 001, PTC 857, Baicalein, VLX 1005, Research programme: 5-B-Cell Lymphoma Inhibitor (LOX Inhibitor), and others.
- B-Cell Lymphoma Therapeutic Assessment: B-Cell Lymphoma current marketed and B-Cell Lymphoma emerging therapies
- B-Cell Lymphoma Market Dynamics: B-Cell Lymphoma market drivers and B-Cell Lymphoma market barriers
Request for Sample PDF Report for B-Cell Lymphoma Pipeline Assessment and clinical trials @ B-Cell Lymphoma therapies and drugs
Table of Contents
1. B-Cell Lymphoma Report Introduction
2. B-Cell Lymphoma Executive Summary
3. B-Cell Lymphoma Overview
4. B-Cell Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. B-Cell Lymphoma Pipeline Therapeutics
6. B-Cell Lymphoma Late Stage Products (Phase II/III)
7. B-Cell Lymphoma Mid Stage Products (Phase II)
8. B-Cell Lymphoma Early Stage Products (Phase I)
9. B-Cell Lymphoma Preclinical Stage Products
10. B-Cell Lymphoma Therapeutics Assessment
11. B-Cell Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. B-Cell Lymphoma Companies
14. B-Cell Lymphoma Key Products
15. B-Cell Lymphoma Unmet Needs
16 . B-Cell Lymphoma Market Drivers and Barriers
17. B-Cell Lymphoma Future Perspectives and Conclusion
18. B-Cell Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com